Fractyl Health Inc. has announced positive results from the 3-month REVEAL-1 Cohort data of its REMAIN-1 pivotal study, focusing on Revita®, a potential weight maintenance therapy. The study suggests that Revita may aid in maintaining or furthering weight loss after discontinuation of GLP-1 drugs. In this cohort, 12 out of 13 participants maintained or lost weight, with six losing additional weight post-GLP-1 therapy. The median weight remained stable, in contrast to the typical 5-6% weight regain expected after stopping GLP-1 therapy. The treatment demonstrated an excellent tolerability profile, with infrequent, mild, and transient treatment-emergent adverse effects. Fractyl Health is preparing for two key upcoming data readouts: the randomized Midpoint Cohort data expected in Q3 2025 and the 6-month primary endpoint data from the Pivotal Cohort anticipated in H2 2026. These results will further evaluate Revita's potential safety and efficacy in post-GLP-1 weight maintenance.